A study found that recent increases in Medicare spending on outpatient cancer care at the end of patients’ lives were driven almost entirely by a type of treatment given to fewer than 1 in 5 patients.
Research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient’s T cells outside the body before reinfusing them, can successfully treat this rare and aggressive cancer.
